Endo International (NASDAQ:ENDP) (TSE:ENL) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 8th. Analysts expect the company to announce earnings of $0.59 per share for the quarter. Endo International has set its FY18 guidance at $2.50-2.60 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.22. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The company had revenue of $714.70 million during the quarter, compared to analyst estimates of $679.72 million. During the same period last year, the company posted $0.93 earnings per share. The firm’s quarterly revenue was down 18.4% compared to the same quarter last year. On average, analysts expect Endo International to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of NASDAQ:ENDP opened at $16.94 on Thursday. Endo International has a twelve month low of $5.27 and a twelve month high of $18.50. The firm has a market capitalization of $3.65 billion, a PE ratio of 4.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.70.
ENDP has been the subject of a number of research reports. ValuEngine upgraded Endo International from a “hold” rating to a “buy” rating in a research note on Wednesday, August 8th. B. Riley raised their target price on Endo International from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. Deutsche Bank set a $11.00 target price on Endo International and gave the company a “buy” rating in a research note on Wednesday, July 18th. Citigroup raised their target price on Endo International from $11.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, BidaskClub lowered Endo International from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 8th. Fifteen analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $14.91.
In related news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.80% of the stock is owned by company insiders.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: Leveraged Buyout (LBO)
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.